Diagnosis of mucormycosis in three children following hematopoietic stem cell transplantation using metagenomic next-generation sequencing

LI Yue, ZHOU Xiao-Hui, WANG Xiao-Dong, WANG Chun-Jing, CAO Ke, LIU Si-Xi

Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (2) : 219-224.

PDF(857 KB)
HTML
PDF(857 KB)
HTML
Chinese Journal of Contemporary Pediatrics ›› 2025, Vol. 27 ›› Issue (2) : 219-224. DOI: 10.7499/j.issn.1008-8830.2408034
CLINICAL EXPERIENCE

Diagnosis of mucormycosis in three children following hematopoietic stem cell transplantation using metagenomic next-generation sequencing

  • LI Yue, ZHOU Xiao-Hui, WANG Xiao-Dong, WANG Chun-Jing, CAO Ke, LIU Si-Xi
Author information +
History +

Abstract

This article reports the clinical characteristics and treatment processes of three cases of mucormycosis occurring after hematopoietic stem cell transplantation in children, along with a review of relevant literature. All three patients presented with chest pain as the initial symptom, and metagenomic next-generation sequencing (mNGS) confirmed the mucycete infection early in all cases. Two patients recovered after treatment, while one succumbed to disseminated infection. mNGS has facilitated early diagnosis and treatment, reducing mortality rates. Additionally, surgical intervention is an important strategy for improving the prognosis of this condition.

Key words

Mucormycosis / Hematopoietic stem cell transplantation / Metagenomic next-generation sequencing / Child

Cite this article

Download Citations
LI Yue, ZHOU Xiao-Hui, WANG Xiao-Dong, WANG Chun-Jing, CAO Ke, LIU Si-Xi. Diagnosis of mucormycosis in three children following hematopoietic stem cell transplantation using metagenomic next-generation sequencing[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(2): 219-224 https://doi.org/10.7499/j.issn.1008-8830.2408034

References

1 Girmenia C, Raiola AM, Piciocchi A, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO)[J]. Biol Blood Marrow Transplant, 2014, 20(6): 872-880. PMID: 24631738. DOI: 10.1016/j.bbmt.2014.03.004.
2 Dignani MC. Epidemiology of invasive fungal diseases on the basis of autopsy reports[J]. F1000Prime Rep, 2014, 6: 81. PMID: 25343038. PMCID: PMC4166943. DOI: 10.12703/P6-81.
3 中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10): 754-763. PMID: 32987477. DOI: 10.3760/cma.j.cn112138-20200627-00624.
4 Valentine JC, Morrissey CO, Tacey MA, et al. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005-2016[J]. BMC Infect Dis, 2019, 19(1): 274. PMID: 30898090. PMCID: PMC6429824. DOI: 10.1186/s12879-019-3901-y.
5 Puerta-Alcalde P, Garcia-Vidal C. Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation[J]. J Fungi (Basel), 2021, 7(10): 848. PMID: 34682269. PMCID: PMC8539090. DOI: 10.3390/jof7100848.
6 Prakash H, Chakrabarti A. Global epidemiology of mucormycosis[J]. J Fungi (Basel), 2019, 5(1): 26. PMID: 30901907. PMCID: PMC6462913. DOI: 10.3390/jof5010026.
7 Petraitis V, Petraitiene R, Antachopoulos C, et al. Increased virulence of Cunninghamella bertholletiae in experimental pulmonary mucormycosis: correlation with circulating molecular biomarkers, sporangiospore germination and hyphal metabolism[J]. Med Mycol, 2013, 51(1): 72-82. PMID: 22686246. DOI: 10.3109/13693786.2012.690107.
8 Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports[J]. Clin Microbiol Infect, 2019, 25(1): 26-34. PMID: 30036666. DOI: 10.1016/j.cmi.2018.07.011.
9 Bao J, Liu C, Dong Y, et al. Clinical manifestations of pulmonary mucormycosis in recipients of allogeneic hematopoietic stem cell transplantation: a 21-case series report and literature review[J]. Can Respir J, 2022, 2022: 1237125. PMID: 35692949. PMCID: PMC9184213. DOI: 10.1155/2022/1237125.
10 Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)[J]. Clin Infect Dis, 2012, 54 Suppl 1: S55-S60. PMID: 22247446. DOI: 10.1093/cid/cir868.
11 Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis, 2019, 19(12): e405-e421. PMID: 31699664. PMCID: PMC8559573. DOI: 10.1016/S1473-3099(19)30312-3.
12 Leeflang MM, Debets-Ossenkopp YJ, Wang J, et al. Galactomannan detection for invasive aspergillosis in immunocompromised patients[J]. Cochrane Database Syst Rev, 2015, 2015(12): CD007394. PMID: 26716951. PMCID: PMC6483812. DOI: 10.1002/14651858.CD007394.pub2.
13 中华医学会检验医学分会临床微生物学组, 中华医学会微生物学与免疫学分会临床微生物学组, 中国医疗保健国际交流促进会临床微生物与感染分会. 宏基因组高通量测序技术应用于感染性疾病病原检测中国专家共识[J]. 中华检验医学杂志, 2021, 44(2): 107-120. DOI: 10.3760/cma.j.cn114452-20201026-00794.
14 Suo T, Xu M, Xu Q. Clinical characteristics and mortality of mucormycosis in hematological malignancies: a retrospective study in Eastern China[J]. Ann Clin Microbiol Antimicrob, 2024, 23(1): 82. PMID: 39210448. PMCID: PMC11363688. DOI: 10.1186/s12941-024-00738-8.
15 Shi Y, Peng JM, Hu XY, et al. Metagenomic next-generation sequencing for detecting Aspergillosis pneumonia in immunocompromised patients: a retrospective study[J]. Front Cell Infect Microbiol, 2023, 13: 1209724. PMID: 38188627. PMCID: PMC10770824. DOI: 10.3389/fcimb.2023.1209724.
16 Ao Z, Xu H, Li M, et al. Clinical characteristics, diagnosis, outcomes and lung microbiome analysis of invasive pulmonary aspergillosis in the community-acquired pneumonia patients[J]. BMJ Open Respir Res, 2023, 10(1): e001358. PMID: 36828645. PMCID: PMC9972439. DOI: 10.1136/bmjresp-2022-001358.
17 Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases[J]. Clin Infect Dis, 2005, 41(5): 634-653. PMID: 16080086. DOI: 10.1086/432579.
18 Muthu V, Agarwal R, Dhooria S, et al. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis[J]. Clin Microbiol Infect, 2021, 27(4): 538-549. PMID: 33418022. DOI: 10.1016/j.cmi.2020.12.035.
19 Lamoth F, Chung SJ, Damonti L, et al. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis[J]. Clin Infect Dis, 2017, 64(11): 1619-1621. PMID: 28199491. DOI: 10.1093/cid/cix130.
20 Groll AH, Pana D, Lanternier F, et al. 8th European conference on infections in leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation[J]. Lancet Oncol, 2021, 22(6): e254-e269. PMID: 33811813. DOI: 10.1016/S1470-2045(20)30723-3.
21 Badali H, Ca?ete-Gibas C, McCarthy D, et al. Epidemiology and antifungal susceptibilities of mucoralean fungi in clinical samples from the United States[J]. J Clin Microbiol, 2021, 59(9): e0123021. PMID: 34232068. PMCID: PMC8373021. DOI: 10.1128/JCM.01230-21.
22 Miller MA, Molina KC, Gutman JA, et al. Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents[J]. Open Forum Infect Dis, 2021, 8(2): ofaa646. PMID: 33575424. PMCID: PMC7863870. DOI: 10.1093/ofid/ofaa646.
23 Kim JH, Benefield RJ, Ditolla K. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection[J]. Mycoses, 2016, 59(11): 726-733. PMID: 27392814. DOI: 10.1111/myc.12524.
24 Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis[J]. Antimicrob Agents Chemother, 2006, 50(1): 126-133. PMID: 16377677. PMCID: PMC1346806. DOI: 10.1128/AAC.50.1.126-133.2006.
25 Ma J, Jia R, Li J, et al. Retrospective clinical study of eighty-one cases of intracranial mucormycosis[J]. J Glob Infect Dis, 2015, 7(4): 143-150. PMID: 26752868. PMCID: PMC4693305. DOI: 10.4103/0974-777X.170497.
26 Mempin R, Kamangar N. Pulmonary artery pseudoaneurysm due to mucormycosis: case report and literature review [J]. J Clin Imaging Sci, 2020, 10: 55. PMID: 33024610 PMCID:PMC7533101. DOI: 10.25259/jcis_127_2020
PDF(857 KB)
HTML

Accesses

Citation

Detail

Sections
Recommended

/